GlobeNewswire: DMK Pharmaceuticals Corporation Contains the last 10 of 191 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T06:22:20ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/12/21/2799977/0/en/DMK-Pharmaceuticals-Regains-Full-Rights-to-Commercialize-ZIMHI.html?f=22&fvtc=4&fvtv=23744DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI2023-12-21T13:15:00Z<![CDATA[Company seeking commercialization partnerships in the United States, Canada, and Europe to expand revenue generation Company seeking commercialization partnerships in the United States, Canada, and Europe to expand revenue generation]]>https://www.globenewswire.com/news-release/2023/11/28/2786908/0/en/DMK-Pharmaceuticals-Regains-Full-Rights-from-US-WorldMeds-for-SYMJEPI-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=23744DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update2023-11-28T13:05:00Z<![CDATA[Now seeking out license opportunities for SYMJEPI® Now seeking out license opportunities for SYMJEPI®]]>https://www.globenewswire.com/news-release/2023/11/14/2779964/0/en/DMK-Pharmaceuticals-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=23744DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update2023-11-14T12:30:00Z<![CDATA[Rebranded company to DMK Pharmaceuticals and appointed inaugural, passionate and committed leadership team to execute on new strategy to reduce opioid related deaths through enhanced sales of ZIMHI® and thus increase shareholder value]]>https://www.globenewswire.com/news-release/2023/11/13/2779211/0/en/DMK-Pharmaceuticals-Announces-Presentation-of-Preclinical-Results-Comparing-Effects-of-DPI-125-on-Opioid-Withdrawal-Behaviors-Versus-Standard-of-Care-for-Opioid-Use-Disorder-at-SfN.html?f=22&fvtc=4&fvtv=23744DMK Pharmaceuticals Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care for Opioid Use Disorder at SfN Neuroscience 20232023-11-13T15:52:06Z<![CDATA[SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, today announced the presentation of preclinical results comparing the effects of DPI-125 on opioid withdrawal behaviors to methadone and buprenorphine, the standard of care for opioid use disorder (OUD), in a poster session at the Society for Neuroscience Annual Meeting (SfN Neuroscience 2023) held November 11-13, 2023 in Washington D.C. DPI-125 is a novel, small-molecule triple (mu, delta and kappa) opioid receptor agonist, being developed for the treatment of opioid use disorder.]]>https://www.globenewswire.com/news-release/2023/10/30/2769094/0/en/DMK-Pharmaceuticals-Announces-Inducement-Option-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=23744DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)2023-10-30T11:30:00Z<![CDATA[SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial-stage biopharmaceutical company, today announced that the compensation committee of the board of directors approved the grant of a stock option on October 23, 2023, to purchase an aggregate of 70,000 shares of common stock to John W. Dorbin, Jr., a newly hired employee who was appointed as General Counsel and Corporate Secretary of the company. The stock option was granted as a material inducement to his acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has a ten-year term and has an exercise price of $0.58 per share, the closing price of the company’s common stock on the grant date. The option vests over a four year period, with the option vesting and becoming exercisable with respect to one-eighth of the shares subject to the option on the six month anniversary of the date of first employment and thereafter monthly with respect to 1/48 of the total number of shares subject to the option, provided that the optionee continues to provide service to the company through the applicable vesting dates. The stock option was granted outside of the company’s 2020 Equity Incentive Plan.]]>https://www.globenewswire.com/news-release/2023/10/20/2764235/0/en/DMK-Pharmaceuticals-Announces-Inducement-Option-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=23744DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)2023-10-20T20:15:00Z<![CDATA[SAN DIEGO, Oct. 20, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial-stage biopharmaceutical company, today announced that the compensation committee of the board of directors approved the grant of a stock option on October 16, 2023, to purchase an aggregate of 151,416 shares of common stock to Seth A. Cohen, a newly hired employee who was appointed as Chief Financial Officer of the company. The stock option was granted as a material inducement to his acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has a ten-year term and has an exercise price of $0.6016 per share, the closing price of the company’s common stock on the grant date. The option vests over a four year period, with the option vesting and becoming exercisable with respect to one-eighth of the shares subject to the option on the six month anniversary of the date of first employment and thereafter monthly with respect to 1/48 of the total number of shares subject to the option, provided that the optionee continues to provide service to the company through the applicable vesting dates. The stock option was granted outside of the company’s 2020 Equity Incentive Plan.]]>https://www.globenewswire.com/news-release/2023/10/19/2763672/0/en/DMK-Pharmaceuticals-Restructures-Executive-Team-to-Support-Next-Phase-of-Growth.html?f=22&fvtc=4&fvtv=23744DMK Pharmaceuticals Restructures Executive Team to Support Next Phase of Growth2023-10-19T20:05:00Z<![CDATA[Seth Cohen is appointed Chief Financial Officer, bringing over thirty years of financial industry experience to DMK, and seasoned corporate lawyer John Dorbin assumes role of General Counsel Corporate Secretary]]>https://www.globenewswire.com/news-release/2023/09/07/2739656/0/en/Adamis-Pharmaceuticals-Changes-Name-to-DMK-Pharmaceuticals-to-Reflect-New-Strategic-Focus.html?f=22&fvtc=4&fvtv=23744Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus2023-09-07T16:00:00Z<![CDATA[Company to begin trading under new ticker symbol “DMK” on September 8, 2023 Company to begin trading under new ticker symbol “DMK” on September 8, 2023]]>https://www.globenewswire.com/news-release/2023/08/21/2728733/0/en/Adamis-Pharmaceuticals-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=23744Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update2023-08-21T13:15:00Z<![CDATA[SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.]]>https://www.globenewswire.com/news-release/2023/08/04/2719209/0/en/Adamis-Pharmaceuticals-Announces-Closing-of-8-0-Million-Public-Offering.html?f=22&fvtc=4&fvtv=23744Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering2023-08-04T17:43:44Z<![CDATA[SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one share of common stock. Each unit was sold at a public offering price of $1.35. The common warrants are immediately exercisable at a price of $1.35 per share and expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants were only purchasable together in this offering, but were issued separately and immediately separable upon issuance.]]>